GlassScriptPhysician profile
Wesley V Cain
NPI 1841854916
$1,930.60
in general payments reported to CMS, 2019-2025
10 companies · $972 in 2025
The $972 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $903 · 2024: $55.72 · 2025: $972.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,131 · Grant: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.60 |
| Grant | $800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,041.79 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $352.19 | 2024-2025 | Fasenra, Airsupra, Tezspire |
| Csl Behring | $152.36 | 2025 | Hizentra, Andembry |
| Glaxosmithkline, LLC. | $84.88 | 2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $72.23 | 2025 | Cuvitru |
| Ars Pharmaceuticals Operations, INC. | $58.50 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $54.24 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $53.56 | 2024-2025 | Dupixent |
| Genentech USA, INC. | $42.00 | 2025 | Xolair |
| Amgen INC. | $18.85 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Cain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.